168 232

Cited 2 times in

Adjuvant Treatment after Surgery in Stage IIIA Endometrial Adenocarcinoma

Authors
 Mee Sun Yoon  ;  Seung Jae Huh  ;  Hak Jae Kim  ;  Young Seok Kim  ;  Yong Bae Kim  ;  Joo-Young Kim  ;  Jong-Hoon Lee  ;  Hun Jung Kim  ;  Jihye Cha  ;  Jin Hee Kim  ;  Juree Kim  ;  Won Sup Yoon  ;  Jin Hwa Choi  ;  Mison Chun  ;  Youngmin Choi  ;  Kang Kyoo Lee  ;  Myungsoo Kim  ;  Jae-Uk Jeong  ;  Sei Kyung Chang  ;  Won Park 
Citation
 CANCER RESEARCH AND TREATMENT, Vol.48(3) : 1074-1083, 2016 
Journal Title
CANCER RESEARCH AND TREATMENT
ISSN
 1598-2998 
Issue Date
2016
Abstract
PURPOSE: We evaluated the role of adjuvant therapy in stage IIIA endometrioid adenocarcinoma patients who underwent surgery followed by radiotherapy (RT) alone or chemoradiotherapy (CTRT) according to risk group. MATERIALS AND METHODS: A multicenter retrospective study was conducted including patients with surgical stage IIIA endometrial cancertreated by radical surgery and adjuvant RT or CTRT. Disease-free survival (DFS) and overall survival (OS) were analyzed. RESULTS: Ninety-three patients with stage IIIA disease were identified. Nineteen patients (20.4%) experienced recurrence, mostly distant metastasis (17.2%). Combined CTRT did not affect DFS (74.1% vs. 82.4%, p=0.130) or OS (96.3% vs. 91.9%, p=0.262) in stage IIIA disease compared with RT alone. Patients with age ≥ 60 years, grade G2/3, and lymphovascular space involvement had a significantly worse DFS and those variables were defined as risk factors. The high-risk group showed a significant reduction in 5-year DFS (≥ 2 risk factors) (49.0% vs. 88.0%, p < 0.001) compared with the low-risk group (< 2). Multivariate analysis confirmed that more than one risk factor was the only predictor of worse DFS (hazard ratio, 5.45; 95% confidence interval, 2.12 to 13.98; p < 0.001). Of patients with no risk factors, a subset treated with RT alone showed an excellent 5-year DFS and OS (93.8% and 100%, respectively). CONCLUSION: We identified a low-risk subset of stage IIIA endometrioid adenocarcinoma patients who might be reasonable candidates for adjuvant RT alone. Further randomized studies are needed to determine which subset might benefit from combined CTRT.
Files in This Item:
T201605703.pdf Download
DOI
10.4143/crt.2015.356
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
Yonsei Authors
Kim, Yong Bae(김용배) ORCID logo https://orcid.org/0000-0001-7573-6862
Cha, Ji Hye(차지혜)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/152925
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links